AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38502720 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization based on residual Jeopardy Score (rJS) 2
Number of subjects: 903
Study 38502720 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete revascularization based on residual Jeopardy Score (rJS) ≥4
Number of subjects: 903
Study 38502720 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI untreated high-grade lesions in the LCX
Number of subjects: 903
Study 38502819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Lavender/Peppermint Aromatherapy Patch
Number of subjects: 0
Study 38502892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 846
Study 38502892 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 846
Study 38502892 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Tenecteplase vs Alteplase
Number of subjects: 846
Study 38502995 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 0
Study 38503247 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive learning method
Number of subjects: 134
Study 38503247 — intervention group
Group type: COMPARATOR
Intervention: Conventional lecture-style teaching
Number of subjects: 134
Study 38503386 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypothermic preservation
Number of subjects: 1061
Study 38503417 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1/DC-vaccine immunotherapy combined with conventional antiglioma treatment (chemoradiation with oral temozolomide 90 mg/m2)
Number of subjects: 10
Study 38503415 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly injections of semaglutide for 30 weeks
Number of subjects: 154
Study 38503415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 38503423 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootle Boot Camp (BBCamp) with movement tracking feedback
Number of subjects: 16
Study 38503423 — intervention group
Group type: COMPARATOR
Intervention: Bootle Boot Camp (BBCamp) without movement tracking feedback
Number of subjects: 16
Study 38503477 — intervention group
Group type: EXPERIMENTAL
Intervention: DDM lens
Number of subjects: 168
Study 38503477 — intervention group
Group type: COMPARATOR
Intervention: SV lens
Number of subjects: 168
Study 38503755 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus everolimus and palbociclib (100 mg palbociclib, 5 mg everolimus, 25 mg exemestane)
Number of subjects: 32
Study 38503755 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus everolimus and palbociclib
Number of subjects: 32
Study 38503870 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help intervention with human guidance (GU)
Number of subjects: 243
Study 38503870 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help intervention with automated messages (AM)
Number of subjects: 243
Study 38503870 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help intervention (GU and AM combined)
Number of subjects: 243
Study 38503870 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WL)
Number of subjects: 243
Study 38503990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit physical activity tracker with feedback on step count
Number of subjects: 63
Study 38503990 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study 38504015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (Arm A)
Number of subjects: 32
Study 38504015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab-relatlimab (Arm B)
Number of subjects: 32
Study 38504015 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both arms)
Number of subjects: 32
Study 38504036 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-15 at H24
Number of subjects: 375
Study 38504157 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 109
Study 38504157 — intervention group
Group type: COMPARATOR
Intervention: psychoeducation
Number of subjects: 109
Study 38504166 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frailty assessment in geriatric patients undergoing noncardiac surgery
Number of subjects: 856
Study 38504173 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV), administered in two doses two months apart.
Number of subjects: 0
Study 38504173 — intervention group
Group type: COMPARATOR
Intervention: Age-/gender-matched HIV-uninfected controls
Number of subjects: 0
Study 38504186 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vessel disease (Group A)
Number of subjects: 89
Study 38504186 — intervention group
Group type: COMPARATOR
Intervention: Multiple vessel disease (Group B)
Number of subjects: 89
Study 38504215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with palliative care education (experimental group)
Number of subjects: 0
Study 38504215 — intervention group
Group type: COMPARATOR
Intervention: Traditional pulmonary rehabilitation (control group)
Number of subjects: 0
Study 38504243 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol pulpotomy
Number of subjects: 39
Study 38504243 — intervention group
Group type: COMPARATOR
Intervention: Zinc-oxide and eugenol pulpectomy
Number of subjects: 39
Study 38504260 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma chlordecone concentrations (highest vs. lowest tertile)
Number of subjects: 182
Study 38504343 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health-assisted lifestyle intervention program consisting of health education, dietary guidance, and physical activity reinforcement for one academic year.
Number of subjects: 6
Study 38504343 — intervention group
Group type: COMPARATOR
Intervention: Usual practice group (control group).
Number of subjects: 6
Study 38504367 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filtration units (24-week home intervention)
Number of subjects: 228
Study 38504367 — intervention group
Group type: COMPARATOR
Intervention: Control units (without HEPA and carbon filters)
Number of subjects: 228
Study 38504367 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filtration units
Number of subjects: 228
Study 38504422 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 38504437 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8233 (antisense oligonucleotide targeting PCSK9)
Number of subjects: 219
Study 38505288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (UDCA)
Number of subjects: 91
Study 38505288 — intervention group
Group type: COMPARATOR
Intervention: Non-Ursodeoxycholic Acid (non-UDCA)
Number of subjects: 91
Study 38505288 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients transplanted between 3 and 6 months ago
Number of subjects: 91
Study 38505303 — intervention group
Group type: EXPERIMENTAL
Intervention: AF with CAD
Number of subjects: 2020
Study 38505303 — intervention group
Group type: COMPARATOR
Intervention: AF without CAD
Number of subjects: 2020
Study 38505522 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg
Number of subjects: 228
Study 38505522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 38505729 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 12151
Study 38505729 — intervention group
Group type: COMPARATOR
Intervention: Placebo or usual care
Number of subjects: 12151
Study 38505928 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-acetaminophen 1000 mg
Number of subjects: 664
Study 38505928 — intervention group
Group type: COMPARATOR
Intervention: ES-acetaminophen 1000 mg
Number of subjects: 664
Study 38505928 — intervention group
Group type: COMPARATOR
Intervention: LG-ibuprofen 400 mg
Number of subjects: 664
Study 38505928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 38506171 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 272
Study 38506171 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 272
Study 38506171 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 272
Study 38506343 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 17282
Study 38506710 — intervention group
Group type: EXPERIMENTAL
Intervention: NOUS-PEV (vector-based personalized vaccine)
Number of subjects: 6
Study 38506889 — intervention group
Group type: EXPERIMENTAL
Intervention: MOABP with an oral regimen of neomycin and metronidazole (n=277)
Number of subjects: 565
Study 38506889 — intervention group
Group type: COMPARATOR
Intervention: MBP plus placebo (n=288)
Number of subjects: 565
Study 38506892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fido chatbot (n=36)
Number of subjects: 81
Study 38506892 — intervention group
Group type: COMPARATOR
Intervention: Self-help book (control group, n=38)
Number of subjects: 81
Study 38506900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic treatments (chemo- and radiotherapy)
Number of subjects: 50
Study 38506900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility preservation treatments (freezing of gametes and gonadal tissue)
Number of subjects: 50
Study 38506900 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 50
Study 38506900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility-preserving procedures
Number of subjects: 50
Study 38506903 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SM group (29/50, 58%)
Number of subjects: 50
Study 38506903 — intervention group
Group type: COMPARATOR
Intervention: Lower SM group (21/50, 42%)
Number of subjects: 50
Study 38506917 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT+TAU
Number of subjects: 160
Study 38506917 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 160
Study 38507025 — intervention group
Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Number of subjects: 76
Study 38507025 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 76
Study 38507100 — intervention group
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Number of subjects: 280
Study 38507109 — intervention group
Group type: EXPERIMENTAL
Intervention: dURS with biopsy
Number of subjects: 2380
Study 38507109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade biopsy
Number of subjects: 2380
Study 38507109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic low-grade tumours
Number of subjects: 2380
Study 38507109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic staging
Number of subjects: 2380
Study 38507109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology outcomes
Number of subjects: 2380
Study 38507441 — intervention group
Group type: EXPERIMENTAL
Intervention: Full MCP (curriculum-activated social network interactions)
Number of subjects: 914
Study 38507441 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic MCP (educational sessions with organic social network interactions)
Number of subjects: 914
Study 38507441 — intervention group
Group type: EXPERIMENTAL
Intervention: Full MCP
Number of subjects: 914
Study 38507441 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care with active monitoring and screenings)
Number of subjects: 914
Study 38507476 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-active potentially inappropriate medication (PIM)
Number of subjects: 8031
Study 38507476 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential subadequate antidepressant dosing
Number of subjects: 8031
Study 38507476 — intervention group
Group type: COMPARATOR
Intervention: CNS-active PIMs
Number of subjects: 8031
Study 38507607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic altitude exposure
Number of subjects: 0
Study 38507662 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-volume irradiation of uninvolved neck
Number of subjects: 0
Study 38507662 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib plus azacitidine
Number of subjects: 643
Study 38507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib plus chemotherapy
Number of subjects: 643
Study 38507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy
Number of subjects: 643
Study 38507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 643
Study 38507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk factors
Number of subjects: 643
Study 38507688 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management of DS
Number of subjects: 643
Study 38507692 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic breathing
Number of subjects: 0
Study 38507692 — intervention group
Group type: COMPARATOR
Intervention: Slow breathing
Number of subjects: 0
Study 38507751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus NSAI (letrozole or anastrozole)
Number of subjects: 426
Study 38507751 — intervention group
Group type: COMPARATOR
Intervention: NSAI alone
Number of subjects: 426
Study 38507751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus NSAI
Number of subjects: 426
Study 38507752 — intervention group
Group type: EXPERIMENTAL
Intervention: scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy)
Number of subjects: 14
Study 38507879 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Rainforest (VRF) application
Number of subjects: 93
Study 38507879 — intervention group
Group type: EXPERIMENTAL
Intervention: White Noise (WN) application
Number of subjects: 93
Study 38507879 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 38507976 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 169
Study 38507976 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective Apnea Hypopnea Index (eAHI)
Number of subjects: 169
Study 38507987 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 218
Study 38507987 — intervention group
Group type: COMPARATOR
Intervention: Symptom deterioration trajectory
Number of subjects: 218
Study 38508135 — intervention group
Group type: EXPERIMENTAL
Intervention: KN046 plus chemotherapy (pemetrexed for non-sq-NSCLC and paclitaxel plus carboplatin for sq-NSCLC)
Number of subjects: 0
Study 38508239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for NSCLC
Number of subjects: 999
Study 38508239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for breast cancer (BC)
Number of subjects: 999
Study 38508239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for colorectal cancer (CRC)
Number of subjects: 999
Study 38508239 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for prostate cancer (PC)
Number of subjects: 999
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 risk score
Number of subjects: 8565
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score
Number of subjects: 8565
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: European Society of Cardiology/European Respiratory Society 2022 risk score
Number of subjects: 8565
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPERA 3-strata risk score
Number of subjects: 8565
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPERA 4-strata risk score
Number of subjects: 8565
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL scores as continuous prediction models
Number of subjects: 8565
Study 38508334 — intervention group
Group type: EXPERIMENTAL
Intervention: Various subgroups analysis
Number of subjects: 8565
Study 38508589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cervical medial branch blocks (USG CMBB)
Number of subjects: 500
Study 38508632 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026
Study 38508632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 38508633 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (TM) with chatbot or TM; Patient navigation (PN) yes or no; repeated offers every 10 or 30 days.
Number of subjects: 0
Study 38508633 — intervention group
Group type: EXPERIMENTAL
Intervention: TM with or without PN; repeated offers every 10 or 30 days.
Number of subjects: 0
Study 38508638 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational physical activity
Number of subjects: 224
Study 38508638 — intervention group
Group type: EXPERIMENTAL
Intervention: Jenkins Sleep Scale
Number of subjects: 224
Study 38508638 — intervention group
Group type: EXPERIMENTAL
Intervention: High occupational physical activity and leisure time physical activity
Number of subjects: 224
Study 38508638 — intervention group
Group type: EXPERIMENTAL
Intervention: High occupational physical activity and low leisure-time physical activity
Number of subjects: 224
Study 38508638 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 224
Study 38508835 — intervention group
Group type: EXPERIMENTAL
Intervention: Givinostat (oral, flexible dose based on weight, twice a day for 72 weeks)
Number of subjects: 179
Study 38508835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, twice a day for 72 weeks)
Number of subjects: 179
Study 38508835 — intervention group
Group type: EXPERIMENTAL
Intervention: Givinostat
Number of subjects: 179
Study 38508835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 38508844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 1347
Study 38508844 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (Enalapril or Valsartan)
Number of subjects: 1347
Study 38508877 — intervention group
Group type: EXPERIMENTAL
Intervention: RAAS blockers
Number of subjects: 88
Study 38508877 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (other antihypertensive drugs)
Number of subjects: 88
Study 38508975 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diacerein
Number of subjects: 0
Study 38508975 — intervention group
Group type: COMPARATOR
Intervention: Topical clobetasol
Number of subjects: 0
Study 38509415 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive blood pressure measurements in patients with AoS
Number of subjects: 149
Study 38509415 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model for AoS detection
Number of subjects: 149
Study 38509415 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive blood pressure measurements in patients without AoS
Number of subjects: 149
Study 38509471 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR (Multidimensional Rehabilitation) programme
Number of subjects: 46
Study 38509471 — intervention group
Group type: COMPARATOR
Intervention: HE (Home-based Exercise) programme
Number of subjects: 46
Study 38509495 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG)
Number of subjects: 51
Study 38509495 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study 38509514 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise without motivational intervention (SUP)
Number of subjects: 120
Study 38509514 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise with motivational intervention (SUP+)
Number of subjects: 120
Study 38509514 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercise without motivational intervention (UNSUP)
Number of subjects: 120
Study 38509514 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercise with motivational intervention (UNSUP+)
Number of subjects: 120
Study 38509514 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 120
Study 38509517 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 219
Study 38509517 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of finerenone with an ACEi or ARB
Number of subjects: 219
Study 38509517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 38509583 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive neurally adjusted ventilatory assist (NIV-NAVA)
Number of subjects: 0
Study 38509583 — intervention group
Group type: COMPARATOR
Intervention: Non-synchronized nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 0
Study 38509605 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 18
Study 38509605 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA scaled delivery model
Number of subjects: 18
Study 38509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 140
Study 38509614 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 140
Study 38509622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk factors (CRFs)
Number of subjects: 1462
Study 38509622 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomics
Number of subjects: 1462
Study 38509622 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic data (GPS)
Number of subjects: 1462
Study 38509662 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based speech therapy app for 1 hour per day, 5 days per week, for 4 weeks, with guideline-based standard stroke care.
Number of subjects: 40
Study 38509662 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline-based stroke care and rehabilitation.
Number of subjects: 40
Study 38509698 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing sleep-disordered breathing (SDB)
Number of subjects: 116
Study 38509698 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing obstructive sleep apnoea (OSA)
Number of subjects: 116
Study 38509698 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing central sleep apnoea (CSA)
Number of subjects: 116